论文部分内容阅读
目的 探讨沙培林膀胱内灌注预防膀胱癌术后复发的疗效、安全性及其可能的机理。方法 对 30例膀胱癌患者术后应用沙培林进行膀胱灌注 ,随访 8～ 2 0个月 ,检测患者灌注前、后尿液中细胞因子 (IL - 2、TNF)的变化情况。结果 无肿瘤复发率为 83.4 % ,复发率为 16 .6 %。所有患者均未出现明显得全身或局部毒副作用。IL - 2灌注前 1.2ng/ml,灌注后 1.5 9ng/ml;TNF灌注前 0 .3ng/ml,灌注后 1.37ng/ml。两者灌注前后比较均有显著性差异 (P <0 .0 5 )。结论 沙培林膀胱内灌注预防膀胱癌术后复发疗效满意 ,病人耐受性好 ,无明显全身或局部不良反应。沙培林膀胱内灌注可通过细胞免疫和体液免疫两个途径达到防治膀胱癌复发的作用。
Objective To investigate the efficacy, safety and possible mechanism of intranasal infusion of sapirin in preventing postoperative recurrence of bladder cancer. Methods Thirty bladder transitional cell carcinoma patients were treated with sperplamine after intravesical instillation. The patients were followed up for 8-20 months. The changes of urinary cytokines (IL - 2 and TNF) in patients with bladder cancer were detected. The results of tumor recurrence rate was 83.4%, the recurrence rate was 16.6%. All patients showed no apparent systemic or local toxic side effects. 1.2ng / ml before IL - 2 perfusion, 1.59ng / ml after perfusion; 0.3ng / ml before TNF perfusion and 1.37ng / ml after perfusion. Both before and after perfusion were significantly different (P <0. 05). Conclusions Saprenaline intravesical instillation is effective in preventing postoperative recurrence of bladder cancer. The patients are well tolerated and have no obvious systemic or local adverse reactions. Sapirin intravesical instillation can be achieved by both cellular and humoral immune control of bladder cancer recurrence.